Natera Reports: Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives

October 8, 2020

Natera a pioneer and global leader in cell-free DNA testing, today announced that Centene, a major healthcare insurance company, has extended coverage of the Panorama non-invasive prenatal test (NIPT) to all pregnant women, including twin pregnancies, representing 24 million additional covered lives.

Natera notes the expanded coverage follows the recent joint guideline released by the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) that supported offering aneuploidy screening options, including NIPT, to all patients, regardless of maternal age or baseline risk. The guideline concluded that NIPT is the most sensitive and specific screening test available for common fetal aneuploidies, and for the first time, endorsed NIPT use in twin pregnancies.

“I am extremely pleased to see that coverage for cell-free DNA screening, which has already been recommended by ACOG for all pregnant women, will now be extended to Medicaid populations,” said Larry Platt, MD, MFM, Clinical Professor in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA. “Broadening coverage to this population is an overdue effort to help resolve established and systemic disparities and inequities in women’s healthcare.”

“The average risk NIPT market is significantly underpenetrated today. We believe expanded insurance coverage and the recent society guideline will enable access for more women, unlocking significant volume growth,” said Ramesh Hariharan, General Manager for Natera’s Women’s Health business.

SourceNatera
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
The addition of Olink to the Synexa Life Sciences technology portfolio demonstrates our continued commitment to strengthening our biomarker and bioanalysis capabilities across several expertise areas including oncology, immuno-oncology, infectious diseases and more.
Oncuria Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.
Liviniti, a national PBM leader in transparency and prescription drug savings, announces a new collaboration with Mindera Health to improve management of moderate-to-severe psoriasis...

By using this website you agree to accept Medical Device News Magazine Privacy Policy